Metabolic syndrome (MetS) a brief discussion

The metabolic syndrome (MetS) is a major and escalating public-health and clinical challenge worldwide in the wake of urbanization, surplus energy intake, increasing obesity, and sedentary life habits. MetS confers a 5-fold increase in the risk of type 2 diabetes mellitus (T2DM) and 2-fold the risk of developing cardiovascular disease (CVD) over the next 5 to 10 years. Further, patients with the MetS are at 2- to 4-fold increased risk of stroke, a 3- to 4-fold increased risk of myocardial infarction (MI), and 2-fold the risk of dying from such an event compared with those without the syndrome regardless of a previous history of cardiovascular events. A version of MetS has a WHO International Classification of Disease (ICD-9) code (277.7) which permits healthcare reimbursement. This shows that the term “metabolic syndrome” is institutionalized and a part of the medical vocabulary. MetS is considered as a first order risk factor for atherothrombotic complications. Its presence or absence should therefore be considered an indicator of long-term risk. On the other hand, the short-term (5-10 years) risk is better calculated using the classical algorithms (Framingham, REGICOR {Registre GIroní del COR}), as they include age, sex, total cholesterol or LDL, and smoking.

MetS is known as a constellation of an interconnected physiological, biochemical, clinical, and metabolic factors that directly high the risk of atherosclerotic cardiovascular disease (ASCVD), (T2DM), and causes mortality. This condition of unhealthy body measurements and abnormal laboratory test results include atherogenic dyslipidemia, hypertension, glucose intolerance, proinflammatory state, and a prothrombotic state. There are several definitions of MetS, but the most commonly used definition presently are from the World Health Organization (WHO), the European Group for the study of Insulin Resistance (EGIR), the National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III), American Association of Clinical Endocrinologists (AACE), and the International Diabetes Federation (IDF).

Endocrinology and Metabolism: Open Access is a peer reviewed journal which focuses on the publication of current research and developments on the endocrine glands and its secretions with their coordination with metabolism and reproduction.

Endocrinology and Metabolism: Open Access Journal is using Editorial Tracking System to maintain quality and transparency to the author in the peer-review process. Review processing will be performed by the editorial board members of the Journal Endocrinology and Metabolism: Open Access or by Reviewers (outside experts in the field). Two independent reviewer’s approval (Minimum reviewer’s approval) followed by editor approval is obligatory for acceptance of any manuscript excluding an editorial.

Journal is now accepting manuscripts for volume 5 for year 2021. We publish minimum of 5 and maximum of 20 articles per issue every month. Submissions to our journal are given high priority during the process.

Submit your manuscript at:

https://www.imedpub.com/submissions/endocrinology-metabolism-open-access.html 

You may also send the manuscript as an attachment to mail endometabol@emedscholar.com

Media Contact
Eliza Grace
Associate Managing Editor
Endocrinology and Metabolism: Open Access
E-Mail: endometabol@emedscholar.com